Diagnostics
Investment will fund the global commercialization of Owlstone Medical’s Breath Biopsy® platform for early disease detection and precision medicine
A new cardiovascular imaging tool could prevent the possibility of people experiencing a second or third heart attack.
Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.
Independent Study Data Shows Noninvasive Test Could Eliminate the Biopsy Needle, Lower Patient Anxiety and Costs
SenzaGen has been notified by the European Center for the Validation of Alternative Methods (ECVAM) authority that due to time constrains their scientific committee (ESAC) will not be able to evaluate tests in the category ”Test Guidelines on Health Effects”, to which GARDskin belongs, this year.
SenzaGen announced today that the company will launch GARDair, the first in vitro test for airway allergies at ESTIV2018, the 20th International Congress on In Vitro Toxicology.
Patients with advanced esophageal squamous cell carcinoma with higher PD-L1 expression can benefit better from leading PD-1 antibody drugs
Owlstone Medical Ltd. announced today the addition of Dr Andy Richards CBE to its Board as a Non-Executive Director.
Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology.
Expedeon AG today announced the signing of a licence and supply agreement for its colloidal gold with South Korea-based PaxGenBio, a privately held, independent developer and supplier of rapid, highly sensitive multiplex diagnostic kits.
PRESS RELEASES